Cytori's Restore II 6 Month Clinical Data Very Encoraging

Today, Cytori Therapeutics released the 6 month interim Clinical Phase II results of one of the many potential applications of its Celution technology that extracts stem and regenerative cells from a patient's own fat tissue (adipose). The Restore II trial was related to the treatment of cell enriched breast reconstruction and was presented at the San Antonio Breast Cancer Symposium. The results where very promising and showed a high level of patient satisfaction. No need for me to interpret the results when you can read the press release here. The clinical data is presented in a video interview and is a must see if you really want to get a better understanding of the clinical results. Cytori also issued a complementary second press release today that that supported the safety of cell enriched fat grafting.

Followers of the Sirtuin Investor know that Cytori Therapeutics was first featured here on September 9, 2009 when CYTX was selling about $3.20 per share. Although I had been following the company for a couple of years it seemed to me that this was the time when the risk/reward characteristics of CYTX, as an investment, looked the most promising. In the September 9th entry, the investment case that was laid out for Cytori was not one based upon a single therapy for a single ailment but on a platform of therapies where doctors around the world could potentially treat multiple ailments and improve upon many cosmetic procedures. To keep thinks in perspective this is just one of those therapies. I urge all those that are new to Cytori go back to that entry as part of their due diligence process to get the bigger picture.

Things continue to look promising for Cytori Therapeutics.